Movement Alert｜GENSCRIPT BIO Rises 3.23% in Regular Trading, AI Drug Discovery Commercialization and CARVYKTI Sales Surge Provide Dual Catalysts

Market Focus

Aug 11

On August 11, GENSCRIPT BIO rose 3.23% in regular trading, trading at 24.98 HKD/share, with turnover of HKD 162 million, extending its recent strong performance.

On the news front, multiple positive catalysts continue to drive the stock. Global AI-driven drug discovery is entering its commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences division covers DNA synthesis, protein production, antibody development, and functional validation, positioning it as a key infrastructure provider converting AI-generated sequences into physical proteins and experimental data. The life sciences division recorded revenue of USD 522 million, up 14.8% year-over-year.

Additionally, associate Legend Biotech reported CARVYKTI Q2 net trade sales of USD 657 million, up 49.4% year-over-year, with first-half sales reaching USD 1.254 billion, up 55.1%. The company is set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1114465186"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114465186\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114465186?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114465186","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 3.23% in Regular Trading, AI Drug Discovery Commercialization and CARVYKTI Sales Surge Provide Dual Catalysts","media":"Market Focus","content":"<p><p>On August 11, GENSCRIPT BIO rose 3.23% in regular trading, trading at 24.98 HKD/share, with turnover of HKD 162 million, extending its recent strong performance.</p><p>On the news front, multiple positive catalysts continue to drive the stock. Global AI-driven drug discovery is entering its commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences division covers DNA synthesis, protein production, antibody development, and functional validation, positioning it as a key infrastructure provider converting AI-generated sequences into physical proteins and experimental data. The life sciences division recorded revenue of USD 522 million, up 14.8% year-over-year.</p><p>Additionally, associate Legend Biotech reported CARVYKTI Q2 net trade sales of USD 657 million, up 49.4% year-over-year, with first-half sales reaching USD 1.254 billion, up 55.1%. The company is set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 3.23% in Regular Trading, AI Drug Discovery Commercialization and CARVYKTI Sales Surge Provide Dual Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 3.23% in Regular Trading, AI Drug Discovery Commercialization and CARVYKTI Sales Surge Provide Dual Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, GENSCRIPT BIO rose 3.23% in regular trading, trading at 24.98 HKD/share, with turnover of HKD 162 million, extending its recent strong performance.</p><p>On the news front, multiple positive catalysts continue to drive the stock. Global AI-driven drug discovery is entering its commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences division covers DNA synthesis, protein production, antibody development, and functional validation, positioning it as a key infrastructure provider converting AI-generated sequences into physical proteins and experimental data. The life sciences division recorded revenue of USD 522 million, up 14.8% year-over-year.</p><p>Additionally, associate Legend Biotech reported CARVYKTI Q2 net trade sales of USD 657 million, up 49.4% year-over-year, with first-half sales reaching USD 1.254 billion, up 55.1%. The company is set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1114465186","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114465186","pubTimestamp":1786412866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, GENSCRIPT BIO rose 3.23% in regular trading, trading at 24.98 HKD/share, with turnover of HKD 162 million, extending its recent strong performance.On the news front, multiple positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易涨3.23%，AI药物发现商业化和CARVYKTI销量激增提供双重催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 11, GENSCRIPT BIO rose 3.23% in regular trading, trading at 24.98 HKD/share, with turnover of HKD 162 million, extending its recent strong performance.On the news front, multiple positive catalysts continue to drive the stock. Global AI-driven drug discovery is entering its commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences division covers DNA synthesis, protein production, antibody development, and functional validation, positioning it as a key infrastructure provider converting AI-generated sequences into physical proteins and experimental data. The life sciences division recorded revenue of USD 522 million, up 14.8% year-over-year.Additionally, associate Legend Biotech reported CARVYKTI Q2 net trade sales of USD 657 million, up 49.4% year-over-year, with first-half sales reaching USD 1.254 billion, up 55.1%. The company is set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}